Neurocrine Biosci…
USUSDNeurocrine Biosciences Inc (MI:1NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 3. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- neurocrine.com
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Centrale
- San Diego, United States
- Amministratore Delegato
- Kyle W. Gano
- Dipendenti
- 2 500
- Fondata
- 1992
- Azioni in Circolazione
- 101.65 Mln al 2026-07-22
- Flottante
- 100.37 Mln
- Capitalizzazione di Mercato
- 14.42 Mld USD
- Insider
- 1.06%
- Investitori Istituzionali
- 102.84%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma Giuridica
- XTIQ
- ISIN
- US64125C1099
- LEI
- 549300FECER0XBN49756
- FCF
- 870 Mln USD
- Debito
- 0
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Blackrock Inc. | 13.49% | 13.71 Mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 6.29% | 6.4 Mln | 2026-06-30 |
| Dodge & Cox Inc. | 5.49% | 5.58 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.89% | 4.97 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 4.47% | 4.55 Mln | 2026-06-30 |
| State Street Corporation | 4.31% | 4.39 Mln | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.9% | 3.96 Mln | 2026-06-30 |
| AQR Capital Management,… | 3.76% | 3.82 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 3.46% | 3.52 Mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.14% | 3.19 Mln | 2026-06-30 |
| Renaissance Technologies… | 2.3% | 2.34 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.27% | 2.3 Mln | 2026-06-30 |
| Geode Capital Management… | 2.1% | 2.14 Mln | 2026-06-30 |
| Two Sigma Investments, L… | 2.04% | 2.08 Mln | 2026-06-30 |
| J.P. Morgan Mutual Fd. I… | 1.34% | 1.36 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 1.33 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.13% | 1.15 Mln | 2026-06-30 |
| JPMorgan Trust II-JPMorg… | 1.1% | 1.12 Mln | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.73% | 739 670 | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.72% | 735 342 | 2026-08-31 |
| GORMAN KEVIN CHARLES (Di… | ≈0.51% | 517 797 | 2026-09-11 |
| GANO KYLE W (Chief Execu… | ≈0.15% | 154 728 | 2026-09-11 |
| LYONS GARY A (Director) | ≈0.12% | 122 141 | 2026-05-21 |
| BENEVICH ERIC S. (Office… | ≈0.07% | 67 297 | 2026-09-11 |
| LIPPOLDT DARIN M (Office… | ≈0.06% | 56 793 | 2026-09-11 |
| RASTETTER WILLIAM H (Dir… | ≈0.04% | 43 678 | 2026-05-21 |
| ABERNETHY MATTHEW C (Chi… | ≈0.04% | 42 808 | 2026-09-14 |
| POPS RICHARD F (Director… | ≈0.04% | 37 798 | 2026-05-21 |
| ROBERTS EIRY WYN (Office… | ≈0.04% | 35 640 | 2025-02-14 |
| COOKE JULIE SMITH (Offic… | ≈0.02% | 24 025 | 2026-09-11 |
Accedi con Google